GlassScriptPhysician profile
Danyaal Moin
NPI 1962729384
$2,918.90
in general payments reported to CMS, 2019-2025
24 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $92.65 · 2021: $38.56 · 2022: $249 · 2023: $548 · 2024: $752 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $699.03 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $575.37 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $334.78 | 2023-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $158.40 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $157.98 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $137.17 | 2023-2025 | |
| Daiichi Sankyo INC. | $130.20 | 2023-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $95.13 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.14 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $59.52 | 2019-2025 | Wainua |
| Irhythm Technologies, INC. | $56.63 | 2022 | |
| Kestra Medical Technology Services, INC. | $53.91 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $53.14 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $48.31 | 2019-2020 | |
| Amgen INC. | $44.41 | 2019-2024 | Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $41.78 | 2023-2025 | |
| Ancora Heart, INC. | $39.27 | 2024 | Accucinch |
| Cvrx, INC. | $35.57 | 2025 | Barostim Neo System |
| One Lambda, INC. | $33.64 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.56 | 2025 | |
| Novo Nordisk INC | $21.35 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.92 | 2023 | Xarelto |
| United Therapeutics Corporation | $15.00 | 2021 | |
| Heartflow, INC. | $13.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danyaal Moin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.